- Home
- MIO vs AMRN Comparison
MIO vs AMRN Comparison
Compare MIO & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIO
- AMRN
- Stock Information
- Founded
- MIO 2021
- AMRN 1989
- Country
- MIO United States
- AMRN Ireland
- Employees
- MIO N/A
- AMRN N/A
- Industry
- MIO Investment Managers
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- MIO Finance
- AMRN Health Care
- Exchange
- MIO Nasdaq
- AMRN Nasdaq
- Market Cap
- MIO 199.2M
- AMRN 216.0M
- IPO Year
- MIO N/A
- AMRN 1993
- Fundamental
- Price
- MIO $11.75
- AMRN $16.90
- Analyst Decision
- MIO
- AMRN Strong Sell
- Analyst Count
- MIO 0
- AMRN 1
- Target Price
- MIO N/A
- AMRN $12.00
- AVG Volume (30 Days)
- MIO 46.0K
- AMRN 174.2K
- Earning Date
- MIO 01-01-0001
- AMRN 07-30-2025
- Dividend Yield
- MIO 4.57%
- AMRN N/A
- EPS Growth
- MIO N/A
- AMRN N/A
- EPS
- MIO N/A
- AMRN N/A
- Revenue
- MIO N/A
- AMRN $214,112,000.00
- Revenue This Year
- MIO N/A
- AMRN N/A
- Revenue Next Year
- MIO N/A
- AMRN N/A
- P/E Ratio
- MIO N/A
- AMRN N/A
- Revenue Growth
- MIO N/A
- AMRN N/A
- 52 Week Low
- MIO $9.18
- AMRN $7.08
- 52 Week High
- MIO $11.36
- AMRN $17.49
- Technical
- Relative Strength Index (RSI)
- MIO 41.62
- AMRN 71.53
- Support Level
- MIO $11.78
- AMRN $16.12
- Resistance Level
- MIO $11.85
- AMRN $17.49
- Average True Range (ATR)
- MIO 0.07
- AMRN 0.96
- MACD
- MIO -0.01
- AMRN 0.05
- Stochastic Oscillator
- MIO 4.91
- AMRN 90.37
About MIO Pioneer Municipal High Income Opportunities Fund Inc.
Pioneer Municipal High Income Opportunities Fund Inc. is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide holders of the Fund's common stock with a high level of current income exempt from regular federal income tax.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.